Spots Global Cancer Trial Database for Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

Official Title: An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma

Study ID: NCT01791894

Conditions

Basal Cell Carcinoma of the Skin

Recurrent Skin Cancer

Interventions

arsenic trioxide

Study Description

Brief Summary: This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing

Detailed Description: PRIMARY OBJECTIVES: I. To determine whether administration of arsenic trioxide (ATO) to patients with basal cell carcinoma is associated with a reduction in Gli messenger ribonucleic acid (mRNA) and protein levels in tumor biopsy samples, when compared to baseline levels. SECONDARY OBJECTIVES: I. To determine whether there is evidence of tumor size reduction of ATO against basal cell carcinoma in humans. OUTLINE: Patients receive arsenic trioxide intravenously (IV) over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.